oncogene-driven mouse B cell lymphoma myc NKT cell adjuvant-based tumor vaccine for treatment of

[1]  L. Metelitsa.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. , 2011, Clinical immunology.

[2]  J. Berzofsky,et al.  Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. , 2011, The Journal of clinical investigation.

[3]  H. Kohrt,et al.  A Cpg-loaded Tumor Cell Vaccine Induces Antitumor Cd4 Ϩ T Cells That Are Effective in Adoptive Therapy for Large and Established Tumors Results Cpg Loading Is Required for Effective Vaccination in Tlr9-competent Hosts , 2022 .

[4]  Christof Fellmann,et al.  Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.

[5]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[6]  I. Frazer,et al.  Secretion of IFN-γ but Not IL-17 by CD1d-Restricted NKT Cells Enhances Rejection of Skin Grafts Expressing Epithelial Cell-Derived Antigen , 2010, The Journal of Immunology.

[7]  T. Wirth,et al.  Advances in the understanding of MYC‐induced lymphomagenesis , 2010, British journal of haematology.

[8]  C. Bogdan,et al.  IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo , 2010, European journal of immunology.

[9]  D. Godfrey,et al.  Raising the NKT cell family , 2010, Nature Immunology.

[10]  J. Berzofsky,et al.  The contrasting roles of NKT cells in tumor immunity. , 2009, Current molecular medicine.

[11]  G. Renukaradhya,et al.  Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. , 2008, Blood.

[12]  D. Neuberg,et al.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.

[13]  M. Smyth.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[14]  J. Berzofsky,et al.  The role of NKT cells in tumor immunity. , 2008, Advances in cancer research.

[15]  R. Steinman,et al.  Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells , 2007, The Journal of experimental medicine.

[16]  L. Kwak,et al.  An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. , 2007, Blood.

[17]  P. Moss,et al.  Immunodeficiency and immunotherapy in multiple myeloma , 2007, British journal of haematology.

[18]  Mark J. Smyth,et al.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma , 2007, Proceedings of the National Academy of Sciences.

[19]  M. Taniguchi,et al.  Tumor Cells Loaded with α-Galactosylceramide Induce Innate NKT and NK Cell-Dependent Resistance to Tumor Implantation in Mice1 , 2007, The Journal of Immunology.

[20]  S. Mattarollo,et al.  Chemotherapy pretreatment sensitizes solid tumor‐derived cell lines to Vα24+ NKT cell‐mediated cytotoxicity , 2006, International journal of cancer.

[21]  R. Steinman,et al.  Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice , 2006 .

[22]  D. Pellicci,et al.  Differential antitumor immunity mediated by NKT cell subsets in vivo , 2005, The Journal of experimental medicine.

[23]  Vrajesh V. Parekh,et al.  Glycolipid antigen induces long-term natural killer T cell anergy in mice. , 2005, The Journal of clinical investigation.

[24]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[25]  R. Steinman,et al.  Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients , 2005, The Journal of experimental medicine.

[26]  T. Iizasa,et al.  A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[27]  P. Stern,et al.  Use of adenoviruses encoding CD40L or IL‐2 against B cell lymphoma , 2004, International journal of cancer.

[28]  S. Targan,et al.  TL1A Synergizes with IL-12 and IL-18 to Enhance IFN-γ Production in Human T Cells and NK Cells1 , 2004, The Journal of Immunology.

[29]  B. Hug,et al.  ETO interacting proteins , 2004, Oncogene.

[30]  V. Callea,et al.  CD1d is expressed on B‐chronic lymphocytic leukemia cells and mediates α‐galactosylceramide presentation to natural killer T lymphocytes , 2004, International journal of cancer.

[31]  T. Juji,et al.  Therapeutic activation of Vα24^+Vβ11^+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity , 2004 .

[32]  M. Tsuji,et al.  Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide , 2003, The Journal of experimental medicine.

[33]  A. Harris,et al.  NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells 1 , 2003, The Journal of Immunology.

[34]  S. Nimer,et al.  Severe and selective deficiency of interferon‐γ‐producing invariant natural killer T cells in patients with myelodysplastic syndromes , 2003, British journal of haematology.

[35]  R. Steinman,et al.  Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .

[36]  M. Dhodapkar,et al.  A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.

[37]  K. Weinberg,et al.  Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells , 2003, Leukemia.

[38]  R. Steinman,et al.  Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs , 2002, Nature Immunology.

[39]  G. Giaccone,et al.  Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. , 2001, Journal of immunological methods.

[40]  I. Serizawa,et al.  Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. , 2001, Oncology research.

[41]  H. Fujiwara,et al.  Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[43]  M. Taniguchi,et al.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. , 1999, Journal of immunology.

[44]  M. Kronenberg,et al.  Immunization with α‐galactosylceramide polarizes CD1‐reactive NK T cells towards Th2 cytokine synthesis , 1999, European journal of immunology.

[45]  G. Trinchieri,et al.  IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. , 1999, Journal of immunology.

[46]  K. Guy,et al.  Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma. , 1986, British Journal of Cancer.

[47]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.